# Corcept Therapeutics

> Corcept Therapeutics is a commercial-stage pharmaceutical company that discovers and develops medicines that treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of cortisol, the body's primary stress hormone. Founded in 1998 and based in Redwood City, California, Corcept built its business on Korlym, the first FDA-approved treatment for hypercortisolism (Cushing's syndrome), and has since discovered more than 1,000 proprietary selective cortisol modulators. In 2026 it won FDA approval for Lifyorli (relacorilant) in platinum-resistant ovarian cancer, extending a single scientific idea - blocking cortisol at the glucocorticoid receptor - from a rare endocrine disease into oncology.

- **Founded:** 1998
- **Headquarters:** Redwood City, California, United States
- **Founders:** Joseph K. Belanoff (Co-Founder, CEO & President), Alan F. Schatzberg (Co-Founder (Stanford collaborator))
- **Team size:** ~500 employees
- **Products:** Korlym (mifepristone), Lifyorli (relacorilant), Relacorilant (Cushing's syndrome), Miricorilant, Dazucorilant
- **Notable:** Developed Korlym, the first FDA-approved treatment for Cushing's syndrome (2012)., Discovered more than 1,000 proprietary selective cortisol modulators over 25+ years., Won FDA approval for Lifyorli (relacorilant) in platinum-resistant ovarian cancer in March 2026.

## Products & services

- **Korlym (mifepristone)** — Once-daily oral tablet and the first FDA-approved treatment for hyperglycemia secondary to endogenous Cushing's syndrome in adults with glucose intolerance or type 2 diabetes who failed or are ineligible for surgery. Designated an Orphan Drug.
- **Lifyorli (relacorilant)** — Selective glucocorticoid receptor antagonist approved in combination with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after prior therapy including bevacizumab.
- **Relacorilant (Cushing's syndrome)** — Next-generation selective cortisol modulator; New Drug Application resubmitted to the FDA for treatment of patients with hypercortisolism (Cushing's syndrome).
- **Miricorilant** — Selective cortisol modulator in clinical development for metabolic dysfunction-associated steatohepatitis (MASH) and other liver disease.
- **Dazucorilant** — Selective cortisol modulator studied for amyotrophic lateral sclerosis (ALS).
- **Exicorilant** — Selective cortisol modulator investigated in oncology and other indications.

## Achievements

- Developed Korlym, the first FDA-approved treatment for Cushing's syndrome (2012).
- Discovered more than 1,000 proprietary selective cortisol modulators over 25+ years.
- Won FDA approval for Lifyorli (relacorilant) in platinum-resistant ovarian cancer in March 2026.
- Phase 3 ROSELLA trial showed a 35% reduction in risk of death and median overall survival of 16.0 months vs 11.9 months for chemotherapy alone.
- Grew to over $760M in annual revenue while self-funding its pipeline.
- Sustained founder-CEO leadership for more than two decades.

## Latest updates

- **2026-03** — FDA approved Lifyorli (relacorilant) with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
- **2026-06** — Corcept resubmitted its New Drug Application for relacorilant as a treatment for patients with Cushing's syndrome.
- **2026-05** — Raised full-year 2026 revenue guidance to $950M-$1.05B on Lifyorli-fueled growth.
- **2026-04** — Reported Q1 2026 revenue of $164.9M (up from $157.2M a year earlier) with a net loss of $31.8M reflecting increased commercial and R&D spend.

## Links

- Website: https://corcept.com
- LinkedIn: http://www.linkedin.com/company/corcept-therapeutics
- Twitter/X: https://twitter.com/Corcept

---

Profile page: https://yespress.io/corcept-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-07-15